Be careful, the rates of influenza syndromes in mid-November are increasing, judging by the medical records in the city and in the hospital. This trend, reflected in the latest bulletin of the French Public Health Service, affects all age groups, but is even more pronounced among those under 15 years of age, especially among children under 5 years of age. Brittany is even in the pre-epidemic phase. Hence the joint call by the public health agency and minister François Braun to “immediately get vaccinated” for at-risk groups.
In France, vaccination against the influenza virus is recommended, especially for people over 65 years of age. Influenza is manifested by body aches, fever, fatigue, cough … which disappear in an average of ten days when a person is in good health. But in debilitated, elderly patients suffering from chronic diseases, it can lead to pneumopathy, severe respiratory failure and increase the risk of cardiovascular disease. The vaccine partially protects against serious forms of the flu, as well as against heart complications, heart attacks, and strokes. Despite everything, many people, including those in the so-called risk group, still do not want to be vaccinated.
Vaccine helps prevent hospitalization and risk of death
- Advertisement -
A new study published in April 2022 in JAMA Network Open confirms that this vaccine does reduce the risk of cardiovascular disease. This meta-analysis covers 6 clinical trials in which 9001 adults were randomly selected to receive either influenza vaccine or placebo. The results show that 3.6% of vaccinated patients suffered from a serious cardiovascular event within twelve months of vaccination compared to 5.4% of those who received placebo alone (no active substance).
- Advertisement -
The Canadian Immunization Research Network previously evaluated vaccine efficacy in adults aged 16 years and older in the 2012, 2013 and 2014 seasons in Canada. According to this study, published in 2018 in the journal Vaccine, even if the effectiveness is not complete, the vaccine contributes to a significant prevention of hospitalization and the risk of death associated with influenza. This efficacy for preventing admission to intensive care was 54.1% in people over 65 years of age and 74.5% for preventing death.